Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 1:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Ventricular Ejection Fraction, LVF, LV Dysfunction, Atrial Enlargement, Conduction Defect, Heart Failure, Valvular Heart Disease, Ischemic Heart Disease, Cardiotoxicity, Myocardial Infarction, Dilated Cardiomyopathy, HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction, Syncope, Remodeling, Cardiac
Interventions
15-minutes of sitting during COR ECG Acquistion
Device
Lead sponsor
Peerbridge Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
8
States / cities
Orange, California • Pasadena, California • Detroit, Michigan + 5 more
Completed Not applicable Interventional Results available

Corticosteroid Injection for Common Upper Extremity Problems

NCT00438672
Conditions
Lateral Elbow Pain
Interventions
Placebo Injection, Steroid (dexamethasone) Injection
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2010
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Renal Transplant Infection
Interventions
Study Group, Control Group
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 99 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Birmingham, Alabama
Conditions
Acute Coronary Syndrome, Coronary Artery Disease
Interventions
Ticagrelor- Delayed Administration, Ticagrelor- Immediate Administration, Optical Coherence Tomography
Drug · Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 79 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Terminated Phase 2 Interventional Accepts healthy volunteers Results available

Vaccine Study for Tick-Borne Encephalitis Virus (TBEV)

NCT01031537
Conditions
Tick-Borne Encephalitis, Encephalitis, Tick-Borne, Tick-Borne Disease, Glycoprotein E, Flavivirus, NSI Protein, Flavivirus
Interventions
FSME-IMMUN 0.5ml Baxter
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 100 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2016
U.S. locations
2
States / cities
Bethesda, Maryland • Hamilton, Montana
Completed Not applicable Interventional Results available

Hypoglossal Nerve Stimulation on Cardiovascular Outcomes

NCT03359096
Conditions
Obstructive Sleep Apnea
Interventions
Therapeutic HGNS, Subtherapeutic 'Sham' HGNS
Device
Lead sponsor
University of Pennsylvania
Other
Eligibility
22 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Chronic Systolic Heart Failure (Dilated Cardiomyopathy)
Interventions
Not listed
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Cleveland, Ohio
Conditions
Hypertension, Vascular Diseases, Cardiovascular Diseases
Interventions
Renal Denervation using the Symplicity Renal Denervation System, Sham Renal Denervation, Renal Angiography
Device · Other
Lead sponsor
Medtronic Vascular
Industry
Eligibility
18 Years to 80 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
3
States / cities
Atlanta, Georgia • Durham, North Carolina • Charleston, South Carolina
Completed Not applicable Interventional Accepts healthy volunteers Results available

Alabama Veterans Rural Health Initiative

NCT01394081
Conditions
Problems With Access to Health Care, Health Behavior
Interventions
Enhanced Engagement and Enrollment (EEE), Administrative Outreach (AO)
Other
Lead sponsor
Tuscaloosa Research & Education Advancement Corporation
Other
Eligibility
19 Years and older
Enrollment
203 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
2
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama
Conditions
Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, NAFLD, Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, NASH
Interventions
AZD7503 Intervention
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 70 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Fall
Interventions
Fall Prevention
Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
65 Years and older
Enrollment
197 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
3
States / cities
Aurora, Colorado • Providence, Rhode Island
Conditions
Breast Cancer, Breast Cancer Female
Interventions
Blood test
Diagnostic Test
Lead sponsor
Immunis.AI
Industry
Eligibility
18 Years and older · Female only
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Durham, North Carolina
Not listed Phase 1Phase 2 Interventional

Lorlatinib Combinations in Lung Cancer

NCT04292119
Conditions
Lung Cancer, Anaplastic Lymphoma Kinase Gene Translocation, ROS1 Rearrangement, Relapsed Cancer, MET Amplification, Resistant Cancer, NSCLC
Interventions
Lorlatinib, Crizotinib, Binimetinib, TNO155
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Pregnancy Related, Pelvic Floor Disorders, Obstetric; Injury, Patient Empowerment
Interventions
Pelvic wand
Device
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Completed No phase listed Observational Accepts healthy volunteers

Contraceptive Hormones, Immunity, and Microbiome Evaluation

NCT03660046
Conditions
Hormonal Contraception
Interventions
Depot medroxyprogesterone acetate (DMPA), Etonogestrel implant (Eng-Implant), Levonorgestrel IUD (Lng-IUD)
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 45 Years · Female only
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
3
States / cities
Atlanta, Georgia
Conditions
Melanoma
Interventions
Fianlimab+cemiplimab
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 7 more
Completed No phase listed Observational Accepts healthy volunteers

Pediatric Type 1 Diabetes and Neurocognitive Complications Cohort Study

NCT04135365
Conditions
Type 1 Diabetes
Interventions
neurocognitive assessment, neuroimaging assessment
Behavioral
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
6 Years to 11 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Nashville, Tennessee
Completed Not applicable Interventional

Healthy Living for You

NCT05917093
Conditions
Diabetes
Interventions
Culturally tailored HLWD
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
2
States / cities
Milwaukee, Wisconsin
Completed Not applicable Interventional Accepts healthy volunteers

Opioid Dependence Treatment Therapies in Pregnancy

NCT03098407
Conditions
Opioid-Related Disorders, Pregnancy
Interventions
Buprenorphine, Methadone
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older · Female only
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Conditions
Asthma
Interventions
Symbicort
Drug
Lead sponsor
Stanford University
Other
Eligibility
12 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Stanford, California
Active, not recruiting No phase listed Observational

Prospective Validation of AKI Prediction

NCT06804200
Conditions
Acute Kidney Injury
Interventions
Not listed
Lead sponsor
Adam C Dziorny
Other
Eligibility
30 Days to 18 Years
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, New York
Conditions
Pancreatic Cancer
Interventions
CPI 613, Oxaliplatin, Irinotecan, 5-flurouracil, Folinic acid
Drug
Lead sponsor
David Bajor, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Completed Phase 2 Interventional Results available

N-Acetylcysteine for Pediatric Trichotillomania

NCT00993265
Conditions
Trichotillomania, Hair Pulling
Interventions
N-Acetylcysteine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
8 Years to 17 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
New Haven, Connecticut
Terminated Phase 1Phase 2 Interventional Results available

Phase 1/2 Dose Confirmation Study of FLT180a in Hemophilia B

NCT05164471
Conditions
Hemophilia B
Interventions
verbrinacogene setparvovec
Genetic
Lead sponsor
Spur Therapeutics
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Los Angeles, California • Tampa, Florida • Ann Arbor, Michigan